Top

Published in:

01-10-2010 | 2010 SSAT Plenary Presentation

Involvement of Osteopontin in the Matrix-Degrading and Proangiogenic Changes Mediated by Nicotine in Pancreatic Cancer Cells

Authors: Melissa Lazar, Jennifer Sullivan, Galina Chipitsyna, Qiaoke Gong, Chee Y. Ng, Ahmed F. Salem, Tamer Aziz, Agnes Witkiewicz, David T. Denhardt, Charles J. Yeo, Hwyda A. Arafat

Published in: Journal of Gastrointestinal Surgery | Issue 10/2010

Abstract

Background

Substantial evidence indicates that exposure to cigarette smoke is associated with an elevated risk of pancreatic ductal adenocarcinoma (PDA). However, the mechanisms underlying the effects of nicotine on the development or progression of PDA remain to be investigated. Previously, we showed that nicotine promotes the expression of osteopontin c (OPNc), an isoform of OPN protein that confers on cancer cells a migratory phenotype. In this study, we explored the potential prometastatic role of nicotine in PDA through studying its effect on the expression of matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) and evaluated the role of OPN in mediating these effects.

Materials and Methods

MMP-9 and VEGF mRNA and protein were analyzed in PDA cells treated with or without nicotine (3–300 nM). Transient transfection and luciferase-labeled promoter studies evaluated the effects of OPNc and OPN protein on the transcription and translation of MMP-9 and VEGF. Real-time PCR and immunohistochemistry were used to analyze the mRNA expression levels and localization of OPN, MMP-9, and VEGF proteins in matched invasive human PDA and surrounding nonmalignant tissues.

Results and Discussion

Nicotine significantly enhanced the expression of MMP-9 and VEGF mRNA and protein in PDA cells. Blocking OPN with siRNA or OPN antibody prevented the nicotine-mediated increase of both MMP-9 and VEGF. Transient transfection of OPNc gene in PDA cells or their treatment with recombinant OPN protein significantly (p < 0.05) increased MMP-9 and VEGF mRNA expression levels and induced their promoter activities. In invasive PDA lesions, MMP-9 mRNA levels were significantly (p < 0.005) higher in smokers vs. nonsmokers. VEGF protein co-localized with MMP-9 and OPN in the malignant ducts and correlated well with their higher levels in invasive PDA lesions.

Conclusions

Our data show for the first time that cigarette smoking and nicotine may contribute to PDA metastasis through inducing MMP-9 and VEGF and suggest that OPN plays a central role in mediating these effects. The presence of OPN as a downstream effector of nicotine that is capable of mediating its prometastatic effects in PDA cells is novel and could provide a unique therapeutic target to control pancreatic cancer aggressiveness, especially in the cigarette-smoking population.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008;52(2):71–96.CrossRef

Wang XL, Wang J. Smoking-gene interaction and disease development: relevance to pancreatic cancer and atherosclerosis. World Journal of Surgery 2005;29:344–53.CrossRefPubMed

Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Prac Res Clin Gastroenterology 2006;20:197–209.CrossRef

US Department of Health and Human Services. The health consequences of using smokeless tobacco: a report of the advisory committee to the Surgeon General [NIH Publication no. 86-2874]. Bethesda, MD: USDHHS; April 1996.

Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and use of tobacco, alcohol and coffee. Intl J Cancer 1990;45:816–20.CrossRef

Silverman DT, Dunn JA, Hoover RN, Schiffman M, Lillemoe KD, Schoenberg JB et al. Cigarette smoking and pancreas cancer: a case control study based on direct interviews. J Natl Cancer Inst 1994;86:1510–6.CrossRefPubMed

Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89(17):1260–70.CrossRefPubMed

Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895–904.CrossRefPubMed

Kelly T, Yan Y, Osborne RL, Athota AB, Rozypal TL, Colclasure JC, Chu WS. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis 1998;16:501–12.CrossRefPubMed

10.

Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97:432–8.CrossRefPubMed

11.

Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumor growth and invasion. Ann Med 1999;31:34–45.CrossRefPubMed

12.

Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43:42–51.CrossRef

13.

Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67–8.CrossRefPubMed

14.

Mira E, Lacalle RA, Buesa JM, de Buitrago GG, Jiménez-Baranda S, Gómez-Moutón C, Martínez-A C, Mañes S. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci. 2004;117(Pt 9):1847–57.CrossRefPubMed

15.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.CrossRefPubMed

16.

Kerbel RS. Tumor angiogenesis. The New England Journal of Medicine 2008;358(19):2039–49.CrossRefPubMed

17.

Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996;2:1679–84.PubMed

18.

Takahashi Y, Kitadai Y, Bucana CD, Cleary ER, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res1995;55:3964–68.PubMed

19.

Chipitsyna G, Gong Q, Anandanadesan R, Alnajar A, Batra SK, Denhardt ST, et al. Induction of osteopontin (OPN) expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int J Cancer 2009;125:276–85.CrossRefPubMed

20.

Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, et al. Expression of a prometastatic splice variant of osteopontin, OPNc, in human pancreatic ductal adenocarcinoma. Surgery 2009;146:232–40.CrossRefPubMed

21.

Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007;26(44):6361–71.CrossRefPubMed

22.

Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res. 2006 Nov;4(11):803–10.CrossRefPubMed

23.

Sánchez-López E, López AF, Esteban V, Yagüe S, Egido J, Ruiz-Ortega M, Alvarez-Arroyo MV. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid Redox Signal. 2005;7(9-10):1275–84.CrossRefPubMed

24.

Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. CancerLett. 2010;295:27–37

25.

Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W, Guo Y. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 2009; 28(38):3412–22.CrossRefPubMed

26.

Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008 Jan 1;68(1):152–61.CrossRefPubMed

27.

Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008;8:241CrossRefPubMed

28.

Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas. 2009;38(6):613–8.CrossRefPubMed

29.

Toomey DP, Manahan E, McKeown C, Rogers A, McMillan H, Geary M, Conlon KC, Murphy JF. Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment. Pancreas. 2010;39:595–603CrossRefPubMed

30.

Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci. 2008;113(1):57–64.CrossRefPubMed

31.

Hukkanen, J., Jacob, P. 3 rd and Benowitz, N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79–115.CrossRefPubMed

32.

Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008;122:889–97.CrossRefPubMed

33.

Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777–94.CrossRefPubMed

34.

Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055–61.CrossRefPubMed

35.

Rocca G, Gaia E, Iuliano R. Increased incidence of cancer in chronic pancreatitis. J Clin Gastroenterol. 1987;9:175–9.CrossRefPubMed

36.

Maisonnneuve P, Lowenfels AB. Chronic pancreatitis and pancreatic cancer. Dig Dis. 2002;20:32–7CrossRef

Title: Involvement of Osteopontin in the Matrix-Degrading and Proangiogenic Changes Mediated by Nicotine in Pancreatic Cancer Cells
Authors: Melissa Lazar
Jennifer Sullivan
Galina Chipitsyna
Qiaoke Gong
Chee Y. Ng
Ahmed F. Salem
Tamer Aziz
Agnes Witkiewicz
David T. Denhardt
Charles J. Yeo
Hwyda A. Arafat
Publication date: 01-10-2010
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 10/2010
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-010-1338-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Involvement of Osteopontin in the Matrix-Degrading and Proangiogenic Changes Mediated by Nicotine in Pancreatic Cancer Cells

Abstract

Background

Materials and Methods

Results and Discussion

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and Methods

Results and Discussion

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2010

Patient and Peri-operative Predictors of Morbidity and Mortality After Esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005–2008

Technique of Minimally Invasive Ivor Lewis Esophagogastrectomy with Intrathoracic Stapled Side-to-Side Anastomosis

One Hundred Thirty Resections for Pancreatic Neuroendocrine Tumor: Evaluating the Impact of Minimally Invasive and Parenchyma-Sparing Techniques

TNF-α Induces Vectorial Secretion of IL-8 in Caco-2 Cells

Eating Behavior in Rats Subjected to Vagotomy, Sleeve Gastrectomy, and Duodenal Switch

National Trends in the Management and Survival of Surgically Managed Gallbladder Adenocarcinoma Over 15 years: A Population-Based Analysis